19 June 2025
Over the past two months, we’ve had the privilege of engaging with the healthcare communications and patient engagement communities at MAPS EMEA, ISMPP Annual, ISPOR US and Patients as Partners Europe. Across continents and conversations, one theme clearly stood out: patient involvement is no longer optional – it is essential.
The expertise of Oxford PharmaGenesis in planning and communicating real-world evidence (RWE) was showcased in a leader published online this month by eyeforpharma.
Every year at Oxford PharmaGenesis, we select a charity so that we can make a donation in lieu of sending cards. This year, we are very pleased to support Evidence Aid, an organization that aims to inspire and enable those guiding the humanitarian sector to apply an evidence-based approach.
Oxford PharmaGenesis has recently become a mentor to a newly established patient group that aims to improve the lives of people affected by certain rare genetic disorders.
The theme of this year’s World Orphan Drug Congress (WODC) Europe was ‘strategy, advocacy and partnering for the world of orphan drugs and rare diseases’, which offered a great opportunity for Oxford PharmaGenesis to showcase our experience in the area of patient engagement.
Oxford PharmaGenesis were thrilled to be in Vienna earlier this month to take part in the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), which this year focused on ‘managing access to medical innovation: strengthening the methodology–policy nexus’.
Oxford PharmaGenesis insights into best practices for the planning and communication of real-world evidence (RWE) studies have been highlighted in an invited editorial, published online in the Journal of Comparative Effectiveness Research (http://www.futuremedicine.com/doi/full/10.2217/cer-2016-0070).
